479064-89-6 Usage
General Description
FMOC-(S)-3-amino-3-(4-fluoro-phenyl)-propionic acid is a chemical compound with potential applications in the field of organic synthesis. It consists of a fluoro-phenyl group attached to a propionic acid backbone, with an amino group in the S configuration. The FMOC (Fluorenylmethyloxycarbonyl) group serves as a protective group in peptide synthesis. FMOC-(S)-3-AMINO-3-(4-FLUORO-PHENYL)-PROPIONIC ACID could be used in the creation of peptides and other bioactive molecules, making it valuable for pharmaceutical research and development. Additionally, the presence of the fluoro-phenyl group could impart specific physical or biological properties to the molecules in which it is incorporated, making it useful in a variety of chemical and biological applications.
Check Digit Verification of cas no
The CAS Registry Mumber 479064-89-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,7,9,0,6 and 4 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 479064-89:
(8*4)+(7*7)+(6*9)+(5*0)+(4*6)+(3*4)+(2*8)+(1*9)=196
196 % 10 = 6
So 479064-89-6 is a valid CAS Registry Number.
InChI:InChI=1/C24H20FNO4/c25-16-11-9-15(10-12-16)22(13-23(27)28)26-24(29)30-14-21-19-7-3-1-5-17(19)18-6-2-4-8-20(18)21/h1-12,21-22H,13-14H2,(H,26,29)(H,27,28)/t22-/m0/s1
479064-89-6Relevant articles and documents
Solid-phase synthesis of a nonpeptide RGD mimetic library: New selective αvβ3 integrin antagonists
Sulyok,Gibson,Goodman,H?lzemann,Wiesner,Kessler
, p. 1938 - 1950 (2007/10/03)
The solid-phase synthesis of a low molecular weight RGD mimetic library is described. Activities of the compounds in inhibiting the interaction of ligands, vitronectin and fibrinogen, with isolated immobilized integrins αvβ3 and αIIbβ3 were determined in a screening assay. Highly active and selective nonpeptide αvβ3 integrin antagonists with regard to orally bioavailability were developed, based on the aza-glycine containing lead compound 1. An important variation is the substitution of the aspartic amide of 1 by an aromatic residue. Furthermore, different guanidine mimetics have been incorporated to improve the pharmacokinetic profile. Exchange of the β-amino acid NH by a methylene moiety in one set of RGD mimetics leads to the azacarba analogue compounds representing a novel peptidomimetic approach, which should increase the metabolic stability.
